Retension Pharmaceuticals (NASDAQ:RTSN) Stock Picked Up by Analysts at Oppenheimer

Investment analysts at Oppenheimer initiated coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a note issued to investors on Tuesday, Benzinga reports. The firm set an “outperform” rating and a $50.00 price target on the stock. Oppenheimer‘s target price indicates a potential upside of 319.82% from the company’s current price.

Separately, Guggenheim began coverage on Retension Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $55.00 price target for the company. Two analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $52.50.

Retension Pharmaceuticals Price Performance

Shares of NASDAQ:RTSN traded up $0.61 during midday trading on Tuesday, hitting $11.91. 44,720 shares of the company’s stock were exchanged, compared to its average volume of 105,304. Retension Pharmaceuticals has a 12 month low of $9.66 and a 12 month high of $18.64.

Insider Buying and Selling at Retension Pharmaceuticals

In other news, Director Franklin Berger bought 10,000 shares of Retension Pharmaceuticals stock in a transaction dated Tuesday, October 13th. The stock was purchased at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at $120,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric Keller bought 20,800 shares of the stock in a transaction dated Tuesday, October 13th. The stock was purchased at an average price of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer owned 423,377 shares of the company’s stock, valued at $5,080,524. The trade was a 5.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.